The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Mitigating immune toxicities associated with T cell-engaging cancer therapies
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the shift from chemotherapy to immunotherapy observed in multiple myeloma (MM) treatment, emphasizing that patients can often avoid chemotherapy at diagnosis and even during relapses. Prof. Landgren then highlights the potential use of an IL-6 receptor antagonist, such as tocilizumab, to reduce common immune toxicities associated with T cell-engaging therapies and potentially enable outpatient administration of these agents. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
